CICC Qiyuan National Emerging Industry Private Equity Venture Capital Investment Fund
中金启元国家新兴产业创业投资引导基金
CICC Qiyuan National Emerging Industry Private Equity Venture Capital Investment Fund (中金启元国家新兴产业创业投资引导基金) is a state-backed guidance fund managed by CICC Capital, the asset management arm of China International Capital Corporation (CICC). It was established to steer capital into China's strategic emerging industries, operating as a fund-of-funds and direct investment vehicle with government policy mandates .
The fund co-leads venture rounds alongside established VCs. In March 2022, it joined Gaorong Capital and CICC Qide Fund to lead the nearly RMB 300 million Series B in Viva Biotech (华龛生物), a Beijing-based 3D cell "smart manufacturing" platform spun out from Tsinghua University . More recently, in March 2024, it hosted the 49th Qiyuan Lecture event in Wuhan, where Harry Wang, founder of Linear Capital, presented on frontier technology investment strategies from a global perspective—suggesting the fund also plays a convening role for policy and industry dialogue in regional innovation hubs .
AI-generated — may contain errors, please verify.
Coverage
Harry Wang, Founder and CEO of Linear Capital, spoke at a CICC Capital Qiyuan Lecture event, sharing frontier technology investment strategies from a global perspective.
On March 25, the 49th Qiyuan Lecture Hall, organized by CICC Qiyuan National Emerging Industry Venture Capital Guidance Fund, was successfully held in Wuhan. The event featured Harry Wang, CEO and founder of Linear Capital, delivering a keynote speech titled *Frontier Tech Investment Strategy from a Global Perspective x China Dividend 2.0*. The event was supported by the Wuhan Donghu New Technology Development Zone Management Committee, and co-hosted by the Hubei Provincial Government Investment Guidance Fund, the Wuhan Donghu New Technology Development Zone Financial Work Bureau, and Wu
Global SaaS, New Brands, and Biopharma Companies Close New Funding Rounds | Rongbao · February
The vitality of spring.
Viva Biotech Completes Nearly RMB 300 Million Series B Funding Round to Accelerate Industrialization of 3D Cell "Smart Manufacturing"
Gaorong Ventures co-led the round.
